Microparticles as a Source of Nuclear Antigens in Systemic Lupus Erythematosus
Microparticles as a Source of Nuclear Antigens in Systemic Lupus Erythematosus
批准号:
7847568
负责人:
DAVID STEPHEN PISETSKY
金额:
$19.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-22 至 2012-03-30
关键词:
AddressAntibodiesAntigen TargetingAntigen-Antibody ComplexAntinuclear AntibodiesAtherosclerosisAutoimmune DiseasesBindingBiological MarkersBiological ModelsBloodBlood CellsCell CommunicationCell LineCell surfaceCellsCessation of lifeClinicalDNADepositionDevelopmentDiseaseFlow CytometryGoalsImmuneImmune Complex DiseasesImmune systemImmunoglobulin GIn VitroIndiumInflammationInterferonsInvestigationKidney DiseasesLupusMembraneMonitorMorbidity - disease rateMusNatureNuclear AntigensNucleic AcidsNucleosomesOrganPathogenesisPathogenicityPatientsPlasmaProductionPropertyPublic HealthRNARoleSerumSignal TransductionSourceStructureSystemSystemic Lupus ErythematosusTissuesVasculitisbody systemcytokineextracellularin vivoin vivo Modelkidney vascular structuremacrophagemortalitynovelnovel strategiesnucleaseparticlepublic health relevanceresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of these investigations is to elucidate the role of microparticles (MPs) as a key source of nuclear antigens in systemic lupus erythematosus (SLE) and characterize these structures as components of pathogenic immune complexes (ICs). MPs are small membrane-structures that are released from cells during cell activation or death. These particles contain DNA and RNA in a form that is protected from extracellular nucleases and allows binding of antinuclear antibodies (ANAs). As such, MPs may form immune complexes that can either deposit in the tissue or promote cytokine production including interferon- 1 (IFN). Because of the value of assessing MPs as target antigens in SLE and their effector function, we are proposing studies to address fundamental questions concerning the nature of ANA binding to MPs and their immunological effects. Three specific aims are proposed: 1) To analyze the binding of antinuclear antibodies to MPs generated in in vitro and in vivo model systems as well as those circulating in patient blood. The MPs in patient blood will be analyzed for binding to a panel of monoclonal anti-DNA and anti- nucleosome antibodies; 2) To analyze the expression of MPs in the blood of patients with SLE, focusing on particles with bound antibody, and determine the relationship to clinical manifestations and disease activity. Using plasma from lupus patients, circulating MPs will be quantified by flow cytometry in terms of cell surface markers, including bound Ig. The number and properties of MPs will be related to disease activity and organ-specific manifestations. Sera of patients with SLE will also be screened for binding to the in vitro-generated particles; and 3) To investigate the effects of ANAs on the immunological activities of microparticles in in vitro systems. The immunological effects of MPs on cytokine production by macrophage cell lines and peripheral blood cells will be assessed in vitro, characterizing effects of monoclonal ANA as well as IgG purified by patient sera. Together, these experiments will provide important new information on a novel group of subcellular signaling structures relevant to the pathogenesis of SLE as well as the development of novel biomarkers and new therapies. PUBLIC HEALTH RELEVANCE: These studies will focus on the role of microparticles in systemic lupus erythematosus (SLE), a prototypic autoimmune disease characterized by inflammation and damage of multiple organ systems. An important mechanism of this disease concerns the formation and deposition of immune complexes that contain nucleic acids. In these studies, we will explore the role of cellular microparticles as a source of this nucleic acid. Understanding the role of microparticles in the immune complex disease will provide information to allow the development of new treatments as well as markers to assess the course of SLE and its renal and vascular complications.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/s10495-010-0470-3
发表时间:
2010-05
期刊:
APOPTOSIS
影响因子:
7.2
作者:
[Ullal, Anirudh J., Pisetsky, David S.]
通讯作者:
Pisetsky, David S.
DOI:
10.1038/nrrheum.2011.108
发表时间:
2011-09
期刊:
Nature Reviews Rheumatology
影响因子:
33.7
作者:
[D. Pisetsky;A. Grammer;Tony C. Ning;P. Lipsky]
通讯作者:
D. Pisetsky;A. Grammer;Tony C. Ning;P. Lipsky
DOI:
10.1007/s12026-010-8184-8
发表时间:
2011-04
期刊:
IMMUNOLOGIC RESEARCH
影响因子:
4.4
作者:
[Pisetsky, David S., Gauley, Julie, Ullal, Anirudh J.]
通讯作者:
Ullal, Anirudh J.
DOI:
10.4414/smw.2011.13256
发表时间:
2011
期刊:
Swiss medical weekly
影响因子:
2.9
作者:
[Pisetsky D]
通讯作者:
Pisetsky D
Cellular Sources of Self Antigen in SLE
-
批准号:10265341
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
-
批准号:8044328
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
-
批准号:8198380
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
MECHANISMS OF AUTOIMMUNITY IN SLE
-
批准号:8398955
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
Microparticles as a Source of Nuclear Antigens in Systemic Lupus Erythematosus
-
批准号:7642593
-
项目类别:
-
资助金额:$16.06万
-
财政年份:2009
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
The Role of Sex in Self Antigen Generation in SLE
-
批准号:7895620
-
项目类别:
-
资助金额:$19.28万
-
财政年份:2009
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
The Role of Sex in Self Antigen Generation in SLE
-
批准号:7708515
-
项目类别:
-
资助金额:$16.06万
-
财政年份:2009
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE GENETICS OF RHEUMATOID ARTHRITIS
-
批准号:7198478
-
项目类别:
-
资助金额:$0.21万
-
财政年份:2005
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
Planing an Early RA Prevention Trial
-
批准号:6912106
-
项目类别:
-
资助金额:$15.4万
-
财政年份:2005
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
The Genetics of Rheumatoid Arthritis
-
批准号:6974048
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2004
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
Strategies for Evaluating and Treating Early Synovitis
-
批准号:6740414
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2003
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
Strategies for Evaluating and Treating Early Synovitis
-
批准号:6804733
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2003
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE IMMUNOMODULATORY EFFECTS OF DNA IN SLE
-
批准号:6874343
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE IMMUNOMODULATORY EFFECTS OF DNA IN SLE
-
批准号:6718481
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE IMMUNOMODULATORY EFFECTS OF DNA IN SLE
-
批准号:6258039
-
项目类别:
-
资助金额:$15.36万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE IMMUNOMODULATORY EFFECTS OF DNA IN SLE
-
批准号:6511099
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
THE IMMUNOMODULATORY EFFECTS OF DNA IN SLE
-
批准号:6632149
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
GENETIC TRAITS OF SIBLING PAIRS W/ RHEUMATOID ARTHRITIS
-
批准号:6565302
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
ADHESION MOLECULES IN THE PATHOGENESIS OF MURINE RHEUMATIOD ARTHRITIS
-
批准号:6348930
-
项目类别:
-
资助金额:$21.36万
-
财政年份:2000
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
MECHANISMS OF ANTI-DNA PRODUCTION IN AUTOIMMUNE MICE
-
批准号:6046137
-
项目类别:
-
资助金额:$20.47万
-
财政年份:2000
-
负责人:DAVID STEPHEN PISETSKY
-
依托单位:
海外基金